{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-063145","form_type":"8-K","ticker":"DERM","cik":"0001867066","company_name":"Journey Medical Corp","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.383817+00:00","generated_at":"2026-06-14T18:34:26.495654+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Journey Medical Q1 net loss $10.1M on revenue decline; DFD-29 topline expected June 2023","bullets":["Net product revenue $12.2M, down from $20.8M YoY, due to higher gross-to-net adjustments and lower Qbrexza, Targadox, Ximino sales.","Net loss $10.1M ($0.57/share) vs. net loss $1.4M ($0.08/share) in Q1 2022; Adjusted EBITDA -$5.3M.","DFD-29 Phase 3 last patient out achieved; topline data expected June 2023; NDA filing planned H2 2023.","SG&A expenses cut to $13.3M (-10% YoY); additional annual savings >$12M vs. 2022 expected from cost reduction initiative.","Fifth Amendment to East West Bank facility: $10M term loan repaid, maturity extended to July 2024, covenants removed except minimum liquidity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-063145","json":"https://secwatch.observer/filing/0001104659-23-063145.json","markdown":"https://secwatch.observer/filing/0001104659-23-063145.md","text":"https://secwatch.observer/filing/0001104659-23-063145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/0001104659-23-063145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/tm2315269d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:34:26.495654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ced62380076504e922dbf548edd1a151628d35d","claim":"Journey Medical Corp amended term loan of $20 million with East West Bank at interest-only payments maturing July 1, 2024.","evidence_excerpt":"Company. On January 12, 2022, the EWB Facility was amended to increase the borrowing capacity of the revolving line of credit to $10.0 million and add a term loan not to exceed $20.0 million. The Company subsequently borrowed the full $20 million under the term loan. On May 16, 2023, the Company entered into the Fifth Amendment to Loan and Security Agreement with EWB","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/0001104659-23-063145-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$20 million"},{"label":"Counterparty","value":"East West Bank"},{"label":"Rate","value":"interest-only payments"},{"label":"Maturity","value":"July 1, 2024"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"8649bea924ac88d3d5983299b2b4b8dfae043227","claim":"Journey Medical Corp reported first quarter ended March 31, 2023 results: revenue $12.2 million, net income $10.1 million, EPS $0.57 per share basic and diluted.","evidence_excerpt":"Total net product revenues were $12.2 million for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/0001104659-23-063145-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$12.2 million"},{"label":"Net income","value":"$10.1 million"},{"label":"EPS","value":"$0.57 per share basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9e994a0768d8c8ac6f27fb75fcab18e1f64e9474","claim":"Journey Medical Corp amended Fifth Amendment to Loan and Security Agreement with East West Bank (effective 2023-05-16).","evidence_excerpt":"On May 16, 2023, the Company entered into the Fifth Amendment to Loan and Security Agreement with EWB and JGP (the \"2023 Amendment\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867066/000110465923063145/0001104659-23-063145-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"East West Bank"},{"label":"Effective","value":"2023-05-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}